Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Give it a rest, there is no scam, no stealing. Everything that has been done is on the up and up!
Alan, wishing you a speedy recovery. I beat Cancer twice and you can do the same.
All the best to you and your family.
So how do investors manage to overcome the obvious deception in OTCBB arena? An indirect approach tends to weaken the path of least resistance before slowly overcoming it. The most effective way is long-term investors slowly accumulating and holding thus drawing the MMs out of its defenses making them as naked as their short position. This is war so this slow accumulation and holding for the long term easily achieves the desired effect to force MMs to cover and knock off the tactics or bury themselves deeper.
Thanks Yooper, straightforward answers and updates from our CEO. Am encouraged that they are working hard to get us a deal for B-OM.I believe it will happen in the near future JMO
Snippits from an article pointing out key factors as to why we lead the competition in developing treatment in the OM space.
Severe OM, two companies differentiate themselves from the rest of the pack in that upcoming phase 3 trials will have primary endpoints of “Incidence” of OM.
This is the important distinction between the rest of the pack looking at “Duration” as their primary endpoint.
Both Innovation Pharmaceuticals and Enzychem life sciences are working to prevent severe OM in the first place rather than moderate the duration of severe OM. “Duration” will be looked at as a secondary endpoint by Innovation and Endzychem.
The article goes on to state that the blockbuster potential resides in stopping the onset of severe OM, as well as ameliorating the condition swiftly should it develop.
Also, I believe Endzychem is an intravenous treatment.
So I have to believe that all is in place to appease a board of Directors who in turn must justify to shareholders millions of dollars being invested in a small Bio trading at 14 cents. 2 potentially blockbuster drugs one of which is FDA approved to move into final trials ( phase 3 trial drugs have an estimated 72% chance of success on average )
Production facilities ramped up and ready to proceed with bulk production to facilitate simultaneous trials on 2 continents.
Confirmation from EMA will be the catalyst and I’m sure we have the go ahead and final approval and that the deal is wrapped up. Just waiting for the announcement…waiting…still waiting…hurry up!
“We are extremely pleased to have been granted this scientific meeting with the EMA, particularly in such rapid fashion,” commented Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals
Might this have something to do with “ Clout “ from a big Pharma over there? Surely our little Bio does not have the ability to command a meeting with the EMA in such quick fashion.
" According to Future Medicine, annual costs associated with treating all types of mucositis in approximately 522,000 patients annually total $13.23 billion."
So will Brilacidin be used for other forms of mucositis?
Great response Crazy. You hit the nail on the head!
Innovation Pharmaceuticals has signed a Drug Product manufacturing contract with CoreRx, for formulating Brilacidin into granular form in unit dose sachets.Was this
Another piece of the puzzle to gain further approval from potential partner in choosing CoreRx?
Perhaps CoreRx was chosen because of the faith one particular big Pharma has in the company and it’s people. We know that Marjolaine Carriere’s is presently a senior scientist at CoreRx as of 2016. Previous to this she spent 12 years plus with Pfizer.
Pfizer oncology also has a strong mandate to advance medicines for the treatment of cancer or as supportive care. Both Brilacidin and Kevetrin would seem to fit these categories and Kevetrin would be an added incentive to sign a deal.
Big pharma “ not interested” not the case. Pfizer has been pursuing a treatment and or cure for oral mucotisis for well over a decade. Going back to funding a trial for the drug Caphosol in 2010.
That seems like an awful large number, have to check that out myself?
My wife told me there are around two dozen big pharmaceuticals running out of Ireland!
Interest in the Brilacidin Franchise—based on the breadth of its treatment potential—was notable. Strong momentum gained as a result of Brilacidin's recent positive topline findings seen in both Inflammatory Bowel Disease (IBD) and Oral Mucositis (OM), coupled with previously successful results achieved in Acute Bacterial Skin and Skin Structure Infection (ABSSSI), has delivered a complementary cross-indication scientific anchoring for each Brilacidin indication in the Company's pipeline.
In particular, Brilacidin-OM received an exceptional degree of attention at the San Francisco shows, further adding to an already robust partnering matrix...Doesn't sound like he's going private.
Agree...Telling us without telling us!
“Thank you for sticking with us, we are working hard to develop a partnership”
“Success ( Success = Money) here not only would help us to complete development of the drug, but also to advance other aspects of our clinical pipeline”
So the meeting was successful, which tells me they can complete development of Brilacidin and advance our clinical pipeline with the Money they will receive. All we are waiting for is confirmation of how much.
Sometimes a drug just needs some tweaking!
"Its turned out to be one of the shrewdest biotech deals in recent memory. After the failed trial, Cubist figured out what went wrong, and won FDA approval of daptomycin in 2003. Sold as Cubicin, the drug now generates close to $1 billion annually"
...Still hope for Prurisol.
In just a few short weeks, we will be convening our Brilacidin-Oral Mucositis End-of-Phase 2 regulatory meeting. Success here not only would help us to complete development of the drug, but also to advance other aspects of our clinical pipeline.
So we have success…Who’s our partner!
Celgene is down 33% on the year, Revlimid makes up about 63% of Celgene's revenue. A huge moneymaker for the company, but they are going to be facing generic competition as soon as 2022, and there are multiple generic competitors. Wouldn’t this Big Pharma love to have a couple of new blockbuster drugs like Brilacidin and Prurisol…My money’s on Celgene for Partnership!
"New approaches to combat antimicrobial resistance urgently need to be developed. Already, more than 700,000 people die each year from infections resistant to most or all antibiotics, and the number is increasing by the day. Antimicrobial resistance is projected to kill more people than cancer by 2050, which would reduce global economic output by between 2 percent and 3.5 percent and severely cripple modern medical and surgical advances.
To date, Big Pharma companies have not successfully developed a new generation of antibiotics"...And we have Brilacidin.
It is not pumping, Anticipation of good news is exciting for those of us vested in this company. Those of you naysayers with no skin in the game should stop being so concerned with a .13 cent company. Relax, we all realize you are here to save us from ourselves. now take a break from your good deeds and go do some Christmas shopping.
So much interest in a .13 cent stock from negative nellies!!
They can not stay away, glued to their computer screen. Must be something big coming our way.
Can take up to 90 days...like he said " not in stone"
?BTD - Most submissions reviewed in 60 days or less*
? Limited types of submissions require 90 days
Briacillian - one dose treatment as effective as seven dose treatment of Daptomycin. "Its turned out to be one of the shrewdest biotech deals in recent memory. After the failed trial, Cubist figured out what went wrong, and won FDA approval of daptomycin in 2003. Sold as Cubicin, the drug now generates close to $1 billion annually, and has become a mainstay for MRSA skin infections and other infections"
Hopefully the science is strong enough to overcome the shortcomings of this company.
Gotta disagree with you Cogs, Briacillian will be a franchise drug and these are what the Big pharma are looking for to carry them for the next 10 plus years.Gonna all go as one package.
Lot's of little rats on this forum!